Fibromyalgia - Competitive Landscape in 2021

This reports provides a data-driven overview of the current and future competitive landscape in fibromyalgia therapeutics.

In fibromyalgia Cannabinoid receptor-1 is a major focus of drug developers. There are 24 drugs in the pipeline with 94% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The increasing prevalence and preference for newer reformulated therapies will drive the market's growth, but wide availability of low cost generic products is expected to limit the uptake of branded therapies.

The publisher’s Fibromyalgia - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Scope

Components of the report include -

• Disease epidemiology
• Marketed drugs assessment
• Pipeline drugs assessment
• Clinical trials assessment
• Commercial assessment
• Social media overview
• Digital marketing overview

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global fibromyalgia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global fibromyalgia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.